---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-22-000045"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:44:05.724263+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q3 revenue $940.7M (+12% YoY); raises FY guidance mid-point to $3.65B

## Summary
- Q3 total revenue $940.7M, up 12% YoY; driven by Xywav, Epidiolex, and Rylaze demand.
- Raises 2022 total revenue guidance mid-point to $3.65B, up from prior range.
- Operating cash flow YTD $930M; cash $899.4M; net leverage ratio 2.9x.
- More narcolepsy patients now on Xywav than Xyrem as of October 2022 milestone.
- Pipeline progress: first patients enrolled in Phase 1 JZP815 and Phase 3 Epidyolex in Japan.

## SEC filing metadata
- accession: 0001232524-22-000045
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252422000045/0001232524-22-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252422000045/jazz-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-22-000045
- JSON: https://secwatch.observer/filing/0001232524-22-000045.json
- Plain text: https://secwatch.observer/filing/0001232524-22-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.